Matrisys Bioscience
505 Coast Boulevard South
Suite 311
La Jolla
San Diego
92037
United States
Tel: 858-456-3919
Website: http://matrisysbio.com/
Email: info@matrisysbio.com
About Matrisys Bioscience
MatriSys Bio is a clinical stage Specialty Biopharmaceutical Company focused on the $142 Billion worldwide dermatology and skin care market.Founded in 2015, the company is developing rational microbiome therapies based on Dr. Richard L. Gallo’s basic and clinical research for the top 5 dermatology and skin care conditions – Acne, Atopic Dermatitis (AD), Rosacea, Psoriasis, and Skin Infections, which have a huge impact on patients’ quality of life. More than 230 million patients suffer from these 5 skin diseases.
YEAR FOUNDED:
2015
LEADERSHIP:
Co-Founder and CEO: Mark Wilson
TECHNOLOGY:
Please click here for MatriSys Bio's technology.
11 articles about Matrisys Bioscience
-
MatriSys Bioscience Co-Founder Richard Gallo, MD, PhD Honored by AAD and AAAAI
3/20/2023
MatriSys BioScience today announced that its scientific co-founder, Dr. Richard Gallo , received the Eugene J Van Scott award for Innovative Therapy of the Skin from the American Academy of Dermatology (AAD).
-
MatriSys Bioscience Announces Corporate and Strategic Update
1/4/2023
MatriSys BioScience today provided a progress update on its three lead programs.
-
MatriSys Bioscience to Present at the 4th Microbiome Movement Skin Health & Dermatology Summit
7/29/2021
MatriSys Bioscience, a company harnessing beneficial bacteria to treat inflammatory skin diseases, announced that the company’s CEO, Philippe Calais, Pharm.D., Ph.D., will present at the 4th Microbiome Movement Skin Health & Dermatology Summit, which will be held virtually August 3-5, 2021.
-
MatriSys Bioscience Names Joyce Rico as Chief Medical Officer
3/25/2021
MatriSys Bioscience, a company harnessing beneficial bacteria to treat inflammatory skin diseases, announced the hiring of Joyce Rico, MD, MBA, FAAD, as Chief Medical Officer.
-
MatriSys Bioscience Expands Licensing Agreement with UCSD School of Medicine to Develop Acne Treatment
3/18/2021
MatriSys Bioscience, a company harnessing beneficial bacteria to treat inflammatory skin diseases, today announced that the company has licensed the compound MSB-3163 from Dr. Richard Gallo’s laboratory at the University of California San Diego School of Medicine.
-
MatriSys Bioscience Raises more than $3 million to Advance its Portfolio of Products to Treat Inflammatory Skin DiseasesFunding will support MatriSys’ growth and platform for its beneficial bacterial therapies
3/11/2021
MatriSys Bioscience, a company harnessing beneficial bacteria to treat inflammatory skin diseases, today announced that it has raised more than $3 million in an oversubscribed bridge financing led by its existing and new investors.
-
MatriSys Bioscience Inc. is pleased to announce that we have been selected as a CONNECT 2020 Cool Company
5/28/2020
MatriSys Bioscience, Inc., a leader in the field of microbiome-based therapeutics is pleased to announce that it was named a 2020 “Cool Company” by Connect/San Diego Venture Group (SDVG). Connect/SDVG is a regional, non-profit organization whose mission is to help innovators and entrepreneurs in Southern California by providing access to investors, mentors and education.
-
MatriSys Bioscience Inc. is pleased to announce that Magda Marquet PhD has been appointed Chairwoman of MatriSys’ Board of Directors
5/26/2020
MatriSys Bioscience, Inc., a leader in the field of microbiome-based therapeutics, is pleased to announce that Magda Marquet PhD has been appointed Chairwoman of MatriSys’ Board of Directors.
-
MatriSys Bioscience is pleased to announce the appointment of Dr. James Mackay to its Board of Directors
5/19/2020
MatriSys Bioscience, Inc., a leader in the field of microbiome-based therapeutics for the treatment of skin conditions, is pleased to announce the appointment of Dr. James Mackay to its Board of Directors.
-
Matrisys Bioscience Announces First Patient Dosed In Phase IIA Clinical Trial With Live Staphylococcus Hominis Bacteria For The Treatment Of Atopic Dermatitis
8/21/2017
-
Matrisys Bioscience Announces Today Publication Of Highly Promising Results Which Could Translate Into Clinically Meaningful Benefits For Eighteen Million Patients With Atopic Dermatitis
2/23/2017